AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0

Eleftha 440mg Injection

Prescription Icon
Prescription Required

Marketer

Intas Pharmaceuticals Ltd

Salt Composition

Trastuzumab (440mg)

Overview Eleftha 440mg Injection

Trastuzumab 440mg injection treats breast and gastric cancers by targeting and destroying HER2-positive cancer cells. Administered intravenously by a healthcare professional, the dosage and frequency are determined individually by your physician, depending on your condition and may vary. Strictly adhere to your prescribed regimen; incorrect usage or overdose can lead to severe adverse effects. Therapeutic benefits may not be immediately apparent, often taking weeks or months to manifest; discontinue use only under medical supervision. Common side effects include nausea, headache, skin rash, sleep disturbances, and increased infection risk. This medication can lower blood cell counts, increasing infection vulnerability, necessitating regular blood tests monitoring blood cell levels, along with heart, liver, and uric acid levels. Report any shortness of breath, cough, chills, or limb swelling to your doctor immediately. Inform your healthcare provider of all other medications you are taking, as interactions may occur. This medication is contraindicated during pregnancy and breastfeeding; reliable contraception is crucial for both partners throughout treatment to prevent conception.

Primary Ingredients of Eleftha 440mg Injection

No text provided. Please provide the text you want me to rephrase.

Uses of Eleftha 440mg Injection

Cancers of the breast and stomach

Major Benefits of Eleftha 440mg Injection:

Administering this medication will be handled by your healthcare provider. Self-medication is not advised.

Common Side effects of Eleftha 440mg Injection:

  • Anemia (low number of red blood cells)
  • Chills
  • Common cold
  • Cough
  • Decreased blood cells (red cells, white cells, and platelets)
  • Diarrhea
  • Fatigue
  • Fever
  • Headache
  • Heart failure
  • Infection
  • Insomnia (difficulty in sleeping)
  • Mucosal inflammation
  • Nausea
  • Rash
  • Stomatitis (Inflammation of the mouth)
  • Taste change
  • Upper respiratory tract infection
  • Weight loss

How to use Eleftha 440mg Injection:

This medication will be administered by your healthcare provider; self-medication is strictly prohibited.

How Eleftha 440mg Injection works:

Oncaspar, a 440mg injectable formulation, is a monoclonal antibody engineered from IgG1. Its mechanism targets HER2, the human epidermal growth factor receptor 2, a protein driving excessive cell growth in breast and gastric cancers. By blocking HER2, Oncaspar eliminates cancerous cells and disrupts multiple downstream signaling cascades crucial for tumor development.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Concomitant use of Eleftha 440mg Injection and alcohol can induce significant somnolence.

PregnancyPregnancyCONSULT YOUR DOCTOR

Administering Eleftha 440mg Injection during pregnancy is contraindicated due to established risk to the fetus. Exceptions may be made in critical circumstances where the potential benefits outweigh the known hazards, at the physician's sole discretion. Physician consultation is essential.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Administration of Eleftha 440mg Injection while breastfeeding is likely inadvisable. Preliminary data from human studies indicate potential transfer of the medication into breast milk, posing a possible risk to the infant.

DrivingDrivingCONSULT YOUR DOCTOR

The effect of Eleftha 440mg Injection on driving ability is undetermined. Refrain from driving if experiencing symptoms impairing concentration or reaction time.

KidneyKidneySAFE IF PRESCRIBED

The use of Eleftha 440mg Injection in individuals with kidney impairment is likely safe. Existing evidence indicates dose modification may not be necessary; however, medical advice is recommended.

LiverLiverCONSULT YOUR DOCTOR

Data regarding the administration of Eleftha 440mg Injection to individuals with hepatic impairment is scarce. Physician consultation is advised.

What if you forget to take Eleftha 440mg Injection :

Omitting a scheduled dose of Eleftha 440mg Injection necessitates contacting your physician.

Facts to Know About Eleftha 440mg Injection

LabelValue
Chemical Category Monoclonal antibody
Developing Habits No.
Treatment Category Cancer Therapeutics
Active Class Monoclonal Antibody HER2/neu (ErbB2) Inhibitor

FAQs on Eleftha 440mg Injection

Eleftha 440mg Injection may cause various side effects including sore throat, fever, chills, fatigue, pale skin, nosebleeds, and unusual bruising or bleeding. Other possible side effects are stomach pain, seizures, hallucinations, muscle cramps and spasms, nausea or vomiting, appetite loss, rapid heartbeat, urine discoloration, decreased or painful urination, and difficulty urinating. Infections may also occur. Contact your doctor immediately if you experience any of these symptoms.
Effective contraception should be used during and for seven months following Eleftha 440mg Injection therapy. Pregnancy planning may resume seven months post-treatment.
Treatment with Eleftha 440mg Injection should continue for one year in early-stage breast cancer patients, or until disease recurrence, whichever comes first. Treatment should not exceed one year.
Eleftha 440mg Injection does not require fasting beforehand. Administration must be by a healthcare professional, under the supervision of a doctor experienced in cancer chemotherapy.
Eleftha 440mg Injection is available in two formulations: intravenous infusion and subcutaneous injection. Always verify the product label to ensure correct administration as prescribed. The intravenous formulation is for intravenous infusion only; it is not for subcutaneous use. Your doctor may change your treatment between intravenous and subcutaneous Eleftha 440mg Injection as clinically indicated.
Eleftha 440mg Injection, a monoclonal antibody targeting the HER2 protein, is ineffective in HER2-negative cancers. Because it works by binding to HER2 receptors on cancer cells, inhibiting their growth and spread, it's only beneficial for patients with HER2-positive tumors.
Using Eleftha 440mg Injection with anthracycline cancer drugs (like doxorubicin) can harm your heart. Therefore, your doctor must assess your heart health before and during treatment.
Cardiac evaluations are required at treatment initiation, every three months during treatment, and every six months post-treatment for 24 months following the final Eleftha 440mg Injection. Patients with pre-existing cardiac conditions require evaluations every 12 weeks.
Eleftha 440mg Injection
18,580
MRP 20,481
9% off